Neumora Therapeutics Says Navacaprant Did Not Achieve Primary Endpoint In KOASTAL-2 Or -3; Company To Discontinue Development Of Navacaprant

Loading news article.

Neumora Therapeutics Says Navacaprant Did Not Achieve Primary Endpoint In KOASTAL-2 Or -3; Company To Discontinue Development Of Navacaprant | WAPE

Article summary